6 03, 2023

#AGBT’23: Illumina

By | March 6th, 2023|Categories: Conferences, Core facilities, Next-generation sequencing|Tags: , |0 Comments

Continuing with my summary of what happened at #AGBT23 here’s my round up of the big announcements from Illumina. Of course whilst much of the data presented at the meeting was generated on an Illumina sequencer there was a very significant amount of non-Illumina data […]

23 02, 2023

@illumina came out fighting at JPM’22 with short and long punches – but I forgot to hit “post”!

By | February 23rd, 2023|Categories: Next-generation sequencing|Tags: , , |1 Comment

Sorry this one is over a year late – but I needed to link to it for my more recent AGBT post!James Illumina has been hugely successful in developing SBS chemistry but their lack of competition in short-read sequencing is being challenged by long-term players […]

29 09, 2022

Illumina hits back with Supernova-Seq (I wish)

By | September 29th, 2022|Categories: Next-generation sequencing|Tags: , |2 Comments

Illumina’s Innovation Roadmapjust finished and the team presented a whole lot of excitement with the new instruments: NovaSeq XPlus (available Q1 2023) and NovaSeq X (later) running XPLEAP-SBS (coming in early 2024 to NextSeq 1000 & 2000 on a new, higher output P4 flow cell) to […]

10 01, 2022

@SingularGenomic is coming to a core facility near you in 2022

By | January 10th, 2022|Categories: Core facilities, Next-generation sequencing|Tags: , , |6 Comments

The new G4 benchtop sequencer from Singular Genomics is here. Sept 17th 2021 saw the first picture of the G4 in the wild from Beth Israel Deaconess Medical Center (see below). For anyone still recovering from a 2021 New Year’s hangover, the G4 is a […]

21 01, 2021

@PacBio new management team knows a thing or two about sequencing ;-)

By | January 21st, 2021|Categories: Next-generation sequencing, Other stuff|0 Comments

I missed the announcement last Summer on Christian Henry’s move to PacBio as their new President & CEO, taking over from Mike Hunkapiller who recently retired – these are some big boots to fill! Christian was was previously Illumina EVP and CFO, having held the CFO […]

25 09, 2020

What is Minimal Residual Disease (MRD)?

By | September 25th, 2020|Categories: Early detection, Epigenomics, MRD, Next-generation sequencing|0 Comments

Many of my followers in the cancer space, especially the Hemes folks, will already understand what MRD is and why it’s important. But for those of you who don’t know I thought an explainer might be helpful. I took inspiration from Keiths COVID qPCR explainer and this […]

21 09, 2020

@illumina buys @GrailBio for $8 billion

By | September 21st, 2020|Categories: Diagnostics Tech, Early detection, Next-generation sequencing|1 Comment

Wow Illumina just spent $8 billion buying GRAIL; arguably the leader in methylation-based early detection of cancer with their Galleri test (read the press release). Get more info over at the website they’ve put together for the deal at transformingcancerdetection.com, which includes a presentation that also highlights […]

10 09, 2020

@10xGenomics buys @CARTANAbio for in situ GX analysis validation

By | September 10th, 2020|Categories: 10X Genomics, Methods and applications, Next-generation sequencing, Single-cell sequencing|0 Comments

CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]

Load More Posts